Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Eribulin Receives Priority Review Status in the US
June 21, 2010
- Erbitux + FOLFIRI Effective for Stomach Cancer in PII
June 21, 2010
- Pfizer, Eisai Launch Lyrica
June 21, 2010
- GL for Non-Clinical Evaluation of Anti-Malignant Tumor Agents Issued
June 21, 2010
- Eplerenone Meets Primary Endpoint Early in PIIIb: Pfizer
June 21, 2010
- Bayer to Expand Packing Line for Chewable Tablets
June 21, 2010
- Clinical Trial Costs Can Be Cut Using iPad: Mr Hasegawa
June 21, 2010
- Lubiprostone Meets Primary Endpoint in PIII in Japan
June 21, 2010
- Asahi Kasei's Pharm Sales to Fall below Target Set in Mid-Term Management Plan
June 21, 2010
- New OTC Drugs Consultation Services Started
June 21, 2010
- Diovan Shows Hypotensive Effects in Elderly Japanese Patients
June 21, 2010
- Rezaltas No. 1 in Both HP, GP Market
June 21, 2010
- Korosho to Consult Medical Societies on 19 Switch OTC Drug Candidates
June 21, 2010
- GenomIdea Receives Grant for Developing DNA Vaccines for Pandemic Flu
June 21, 2010
- MSNW: Dispensing Pharmacy Business Boosts Sales, Profits
June 14, 2010
- Kyowa Kirin Licenses KW-6002 to BLS in North America
June 14, 2010
- JDS HbA1c Values to Be Replaced with NGSP HbA1c Values
June 14, 2010
- Astellas to Copromote Kaketsuken's Vaccines in Kyushu
June 14, 2010
- Novartis to Drive Business by Expanding Range of Indications for Afinitor: Mr Asakawa
June 14, 2010
- Naoto Kan Elected 94th Prime Minister of Japan
June 14, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…